Aptevo Therapeutics shares spike on promising trial results for leukemia therapy

Aptevo Therapeutics (NASDAQ:APVO) shares jumped 16% after reporting encouraging Phase 1b/2 RAINIER trial results for mipletamig, its CD123 x CD3 bispecific antibody, in newly diagnosed acute myeloid leukemia (AML) patients. Cohort 3 demonstrated a 100% remission rate, with 40% achieving minimal residual disease (MRD)-negative status, alongside a favorable safety profile showing no dose-limiting toxicities. This data positions mipletamig as a potentially differentiated and highly effective frontline AML therapy, suggesting significant clinical and commercial upside for the company.

Analysis

Aptevo Therapeutics (APVO) has reported exceptionally strong interim data from its Phase 1b/2 RAINIER trial, triggering a 16% share price increase to $1.67. The trial evaluates its first-in-class bispecific antibody, mipletamig, for newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. The key finding is that Cohort 3 achieved a 100% remission rate, a powerful efficacy signal in this difficult-to-treat population. Importantly, 40% of these patients attained minimal residual disease (MRD)-negative status, a critical metric associated with deeper, more durable responses and improved long-term survival outcomes. This level of MRD-negativity significantly de-risks the asset. Furthermore, the therapy demonstrated a favorable safety profile, with no dose-limiting toxicities or cytokine release syndrome observed when combined with the standard-of-care venetoclax and azacitidine backbone. The consistent positive results across escalating dose cohorts, coupled with management's confident outlook on changing the AML treatment paradigm, suggest mipletamig has a differentiated profile with significant clinical and commercial potential. The progression to Cohort 4 enrollment represents a clear near-term catalyst for further data.

Key Decisions for Investors

• The combination of a 100% remission rate and 40% MRD-negativity represents a significant clinical de-risking event, warranting a re-evaluation of Aptevo's valuation to reflect a higher probability of success for mipletamig.
• Investors should monitor for upcoming data from Cohort 4, as a replication of these positive efficacy and safety results at a higher dose would serve as a major near-term catalyst and further validate the therapy's best-in-class potential.
• Despite the highly encouraging results, it is crucial to recognize that APVO remains a clinical-stage biotechnology company with inherent binary risk, and positions should be sized to account for potential volatility tied to future clinical and regulatory outcomes.